The clinical success of perispinal administration of opiates for pain relief has demonstrated the power of manipulating the neurochemistry of the spinal cord. This article briefly discussed reasons for increased interest in new spinal agents and some of the issues associated with determining their clinical safety.
When considering toxicity of new agents that are likely to be applied near the spinal cord, that is, by the perispinal route of administration, we must make the following general assumption: any new agent administered by the perispinal route, at concentrations adequate to produce the desired pharmacologic effect, must be assumed to be toxic to the spinal cord. This assumption must be made even if the agent has been demonstrated to be safe when administered systemically in humans. Although this assumption is likely to be proven wrong in most instances, the devastating impact of spinal cord trauma as a result of drug administration by the perispinal route demands that we have solid evidence of the absence of spinal toxicity before new agents are administered by that route. Why do we need new spinal agents?
While some may question the need for new agents to be administered perispinally, there are at least three factors that are likely to contribute to increased efforts to modify the local pharmacology of the spinal cord. These efforts are likely to involve substances in which spinal safety has not been demonstrated. Until Yaksh and Rudy [1] demonstrated the behavioral analgesic effects of the direct spinal action of narcotics, the spinal cord was thought of by many as a simple cable. Although it was clear that local anesthetics could act to block sensory and motor activity within the spinal cord, little attention was given to the clinical importance of the pharmacology of spinal sensory processing. Documentation of the direct action of opiates on spinal sensory processing [2, 3, 4] led to the behavioral work by Yaksh and Rudy and revealed the potential importance of a better understanding of how the nervous system communicates within the spinal dorsal horn. It is now obvious that the pharmacology of spinal sensory processing provides unique opportunities to influence sensory experience.
The first reason for the use of new spinal agents is our increasing understanding of the complexity of the pharmacology of spinal sensory processing. If we focus only on Cfibers that are associated with transmission of information about noxious mechanical and thermal stimuli in the periphery, the complexity of the system is quickly apparent. There are at the least seven neurotransmitters that are likely to be released by those C-fibers (glutamate, aspartate, substance P, neurokinin A, neurokinin B, CGRP, and somatostatin).
The presynaptic terminal of the C-fibers, in addition to releasing those neurotransmitters, also contains a series of receptors that may be acted upon by opioid, alpha adrenergic, GABA, cholecystokinin, serotonin, and excitatory amino acid neurotransmitters. Activation of some of those receptors will enhance the transmission of information from primary afferents to second order neurons. Most are likely to depress that transmission.
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Haven, Connecticut 06520-8051. 457 The second order neurons that will receive the message from the C-fibers also have a large number of receptors, the activation of which may modify their response to the incoming message. Activation of excitatory amino acid AMPA, NMDA; neuroKinin NK1, NK2, NK3; opiate mu, delta, kappa; alpha2 adrenergic; gamma aminobutyric acid GABAA, GABAB; serotonin, 5HT1, 5HT3; or cholecystokinin CCKA, CCKB receptors on the second order neurons may either enhance or depress the transmission of information from the C-fibers. Neurotransmitters that may produce physiological effects at those sites could be released by interneurons, descending modulatory systems or other primary afferents. The above mentioned relationships recently have been summarized graphically by Dickenson [5] .
The above very brief description of interactions that are likely to occur at the first synapse between a primary afferent carrying information about pain and second order neurons demonstrates the extremely rich pharmacology that appears to be involved in the normal transmission of information about pain. For the basic scientist, this rich interaction of receptors and neurotransmitters provides a fascinating research tool; for the clinician, it provides unique opportunities for drug interactions and the possibility of enhanced pain control by the appropriate use of drug combinations administered by the perispinal route.
It is important to recognize that the normal transmission of information in the spinal dorsal horn is assumed to be depend upon interactions among many of the above mentioned transmitter systems. It is also likely that the most effective pharmacological interventions may result from drug combinations rather than a single agent. This is especially true if synergistic interactions seen in animal studies [6] are also present in the clinical setting.
While some may argue that new agents or combinations are not needed for the management of acute postoperative pain, it is clear that difficult to manage chronic pain may come under better control if such strategies are made available. We must, therefore, assume that one of the driving forces behind the use of new spinal agents will be an effort to provide better analgesia by perispinal drug administration.
A second reason for a continuing evaluation of possible new perispinal drugs relates to the significant plasticity that has been demonstrated in the spinal dorsal horn and the possible role that such plasticity plays in some chronic pain states. This plasticity is evident in many ways. Clinically, it has been best demonstrated in a study from Campbell's group [7] in which they reported that, in some patients, activity in large myelinated fibers is responsible for the transmission of information that is ultimately interpreted as pain. The hyperalgesia associated with nerve injury in those patients was clearly signalled by A-beta fibers, fibers that normally would not be associated with signaling pain. An interpretation of those findings is that the nerve damage caused a change in the way that the central nervous system processed information. That plasticity may be a cause of some chronic pain states.
Plasticity is likely to play an important role in some forms of chronic pain. The plasticity, itself, although anatomical in some instances, is likely in a large number of cases to be the result of changes in the neurochemistry of sensory transmission at the spinal level. [8] . Efforts to "correct" plasticity associated with chronic pain will be an additional driving force behind the testing of new spinal agents.
The third reason for new spinal agents, and one that is often overlooked, relates to spinal cord trauma. There is now excellent evidence to suggest that very early intervention is likely to reduce the amount of damage resulting from spinal cord trauma. [9] . Spinal cord trauma may result in both loss of function as well as both acute and chronic pain. In addition to the effects of mechanical trauma, it is now clear that resulting derangements in neurochemistry contribute to the overall level of trauma [10] . As If we assume that new agents are to be administered by the perispinal route, we then need to consider how we are to know that these new agents are safe. As reviewed recently at a satellite meeting to the Seventh World Congress on Paina, Gordh, Eisenach, and Yaksh discussed a number of issues that need to be dealt with when we consider safety of perispinal drug administration. A number of those issues are relevant to this presentation and are discussed below. Preclinical animal studies First and foremost, animal studies are required. The purpose of these animal studies is to define the maximum dose that does not cause toxicity. We must assume that toxicity will be proportional to the local concentration of the agent or agents and the duration of exposure to them.
An extremely important aspect of these tests and one that unfortunately is frequently left out is a positive control. In situations in which knowledge of the drug under study provides some sense of what the acute toxicity may be, it is essential that a positive control be included to guarantee that the test system is sensitive enough to be able to demonstrate the presence of the expected toxicity.
At the very least, three separate pieces of information should be obtained from animal studies. The first relates to behavioral pathology. Dose ranging from the subtoxic to the toxic needs to be employed in order to determine what behavioral changes are likely to be produced by the perispinal administration of the agent under study.
The second area of interest, and one that is frequently not attended to, is spinal cord blood flow. This is especially important since it is likely that combinations of agents will be administered perispinally. An individual agent may reduce spinal cord blood flow without producing adverse effects but when combined with another agent that same reduction in blood flow may be toxic. It is, therefore, important to examine the effects of new agents and combinations on spinal blood flow.
The While the purpose of the animal studies is to define the maximum dose that does not cause acute toxicity, we are always limited by the realization that there may be toxicities that have not been identified because the doses have not been taken to a higher level, (i.e., Has the maximum dosing range been used?). It may not be possible to define a maximum dose range, but the pharmacology of the agent under study may be provide some indication of expected side effects. In those situations those side effects may be defined as the limiting factors in the dose ranging so that there is a rationale behind the choice of a particular maximum dose range. Clinical studies
Having defined the maximum dose that does not cause toxicity in animal studies, it is now time to pursue information about the possible toxicity of the agent in humans. These studies, which have been referred to as Phase I studies, have a single purpose. That purpose is to define the safety and side effects of the agent. Although information about efficacy may be obtained in Phase I trials their only purpose is to examine safety. Because of the nature of the experiment, the study is open labeled and would be expected to employ a dose range from subtherapeutic levels to concentrations where limiting side effects would be observed. Of particular importance here, the preclinical animal work should have hinted at the side effects and prior to initiation of these studies there needs to be a plan in place to respond to expected side effects.
An unresolved question focuses on the most appropriate individuals to be included in a Phase I study. Three choices are typically used: terminally ill patients who may derive some benefit from the treatment, patients with medical problems that could benefit from the treatment, and volunteers who, beyond the financial reward for participation in the tests, will derive no benefit from the treatment. There are positive and negative scientific and ethical issues associated with choosing the patient population for Phase I trials. We need to be concerned with the coercive effect of money if volunteers are employed. Nonterminal patients may feel forced to participate because of the trust they place in their doctors. When determining the patient population that is to be used, we need to remember that the purpose of Phase I trials is not to determine efficacy. It is only to determine the safety and side effects of the agents.
Phase II testing provides an opportunity, in a small number of patients, to begin to define the efficacy of the agents under study. It is important that Phase II studies be blinded. Finally, Phase III studies, which will include larger numbers of patients, will focus on both efficacy and the safety and therefore will require placebo controlled studies wherever possible.
Although the perispinal administration of opiates for the relief of pain is now a widely accepted technique, the development of that technique does not provide the best example of how toxicity studies should be conducted. The model that this author feels should be followed in an evaluation of safety and efficacy of new agents for spinal administration is provided by work done in evaluating alpha adrenergic agonists. Gordh [11] [12] [13] Eisenach [14] [15] [16] [17] [18] and colleagues, working independently, have provided us with a wealth of information about the safety and efficacy of the spinal administration of alpha adrenergic agonists for the relief of pain. Their work provides an ideal model for anyone interest-ed in testing of additional agents for the perispinal administration of drugs. While the work is demanding, and the results are not immediately available to the clinical world, as indicated at the outset, we must assume that any new agent at a concentration adequate to produce analgesia will be toxic to the spinal cord if administered by the spinal route.
Unfortunately, many substances have been administered to humans by the spinal route in small clinical studies that have demonstrated neither safety nor efficacy. As we look at those studies, we need to recognize that there are least three major flaws in their usage and although they may continue to appear in the literature we must be adamant in insisting that they not be considered as the acceptable way of demonstrating the lack of toxicity of new agents for administration of the perispinal route. Typically, these small clinical studies have sample size that is extremely limited. Secondly, the studies are typically not designed to demonstrate safety but rather are an attempt to show that one or two limited doses of the drugs produce a desired effect. These results however are frequently obtained in the absence of blinded controls. Perhaps most importantly the studies rarely employ follow up in order to determine both short term and long term toxicities that may be associated with these drugs.
The pharmacology of spinal sensory processing is an extremely complex area. The complexity provides both a level of frustration as we attempt to understand how it works but also a unique series of opportunities to better regulate various derangements in sensory processing that are seen in the clinical setting. It is our responsibility to make sure that the testing of new agents for perispinal administration is carried out in a scientific fashion that will demonstrate clearly both the lack of toxicity and the efficacy of an individual agent prior to its widespread usage clinically.
